The Centers for Medicare & Medicaid Services (CMS) is implementing a groundbreaking program that will cover up to $500 worth of hemp-derived products for eligible Medicare patients, starting April 1, 2026. This initiative has drawn significant attention, including remarks from Mehmet Oz, who has been vocal about healthcare reforms.
The program primarily focuses on CBD products but also permits a limited amount of THC, specifically a maximum of 0.3% delta-9 THC by dry weight and 3 mg total THC per serving. The announcement comes amid ongoing debates about the legality and efficacy of hemp products in healthcare.
In a recent government brief, officials stated that the anti-cannabis organizations, including Smart Approaches to Marijuana (SAM), do not have standing to challenge the Medicare hemp coverage policy. This decision follows individual plaintiff David Evans’ claims of standing as a Medicare recipient, which federal agencies have rejected, arguing that he has not been harmed by the program.
Judge Trevor N. McFadden has already dismissed requests for a temporary restraining order to prevent the program’s launch. The government maintains that CMS does not pay for hemp products under the Beneficiary Engagement Incentive (BEI), meaning providers will furnish eligible products at their own cost.
The Medicare hemp program was announced as part of a broader initiative to enhance access to full-spectrum CBD products, following an executive order signed by former President Donald Trump. This move marks a significant shift in how Medicare approaches alternative therapies, especially as the White House Office of Management and Budget has engaged in discussions regarding the Food and Drug Administration’s (FDA) enforcement policy on CBD products.
In response to the program, Mehmet Oz emphasized the importance of patient choice and access to alternative treatments. He stated, “This program could provide much-needed relief for patients seeking alternatives to traditional medications, especially those managing chronic conditions.”
As the launch date approaches, the FDA has issued guidance indicating it does not intend to interfere with the Medicare hemp-derived products coverage plan. This has been met with mixed reactions from various stakeholders, including pharmaceutical giants like Merck and Sanofi, who are closely monitoring the implications for their products.
While the Medicare hemp coverage program is set to provide new options for beneficiaries, the controversy surrounding its implementation continues to unfold. As officials prepare for the rollout, the healthcare community is watching closely to see how this initiative will impact patient care and the broader healthcare landscape.
